Launch of Phase 2 SMA Industry Collaboration Announced

Leave a Comment / Front Page News /

Cure SMA is pleased to announce the launch of Phase 2 of our SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, Cure SMA, and other nonprofit organizations, to share information, ideas, and data. The SMA Industry Collaboration works together to address scientific, clinical and regulatory topics that […]

Launch of Phase 2 SMA Industry Collaboration Announced Read More »

2017 Annual SMA Conference Booklet Now Posted

Leave a Comment / Conference, Front Page News /

The 2017 Annual SMA Conference Booklet is now posted. The booklet includes: A complete schedule with information about the special events we’ve got planned including: the Family Friendly Research Poster Session, Saturday Night at Magic Kingdom Park and Sunday’s Newborn Screening Symposium Information on Saturday afternoon panels focusing on SMA drugs in development and drug

2017 Annual SMA Conference Booklet Now Posted Read More »

SMA Newborn Screening Moves Forward in Missouri and Florida

Leave a Comment / Advocacy, Community Awareness, Front Page News /

The spinal muscular atrophy community is celebrating significant progress toward adding SMA to newborn screening panels in two states. Missouri to Become the First State to Screen for SMA In Missouri, Senate Bill 50 has been passed by both the Missouri House and Missouri Senate, and is currently awaiting the governor’s signature. This bill would

SMA Newborn Screening Moves Forward in Missouri and Florida Read More »

AveXis Announces Alignment with the FDA on Company’s GMP Commercial Manufacturing Process for AVXS-101

Leave a Comment / Front Page News, Research /

AveXis today announced alignment with the U.S. Food and Drug Administration (FDA) on the company’s Good Manufacturing Practice (GMP) commercial manufacturing process for AVXS-101 following the receipt of minutes from the Type B Chemistry Manufacturing and Controls (CMC) meeting. This alignment includes support for the proposed commercial manufacturing process, the proposed analytical methods and corresponding

AveXis Announces Alignment with the FDA on Company’s GMP Commercial Manufacturing Process for AVXS-101 Read More »

Update: President’s Budget Proposes Significant Cuts to Federal Health Programs That Are Critically Important to SMA Patients and Families

Leave a Comment / Advocacy, Front Page News /

The President recently released his detailed budget proposal for Fiscal Year 2018, which proposed significant funding cuts to numerous federal programs, including many that have a direct impact on the health and well-being of individuals and families affected by SMA. The federal Fiscal Year runs from October 1, 2017 through September 30, 2018. Of serious

Update: President’s Budget Proposes Significant Cuts to Federal Health Programs That Are Critically Important to SMA Patients and Families Read More »

Anthem Updates Insurance Policy for Spinraza

Leave a Comment / Advocacy, Front Page News /

Anthem Inc. recently announced an updated insurance policy for the use of Spinraza (nusinersen) for treatment of spinal muscular atrophy. The revised policy expands criteria for treatment to onset of SMA-associated signs and symptoms before 21 months of age; the previous policy’s criteria for treatment of onset symptoms was 6 months or younger. In 2016,

Anthem Updates Insurance Policy for Spinraza Read More »

European Commission Grants Marketing Authorization for Spinraza, Making it First Approved SMA Treatment in the European Union

Leave a Comment / Front Page News /

Biogen announced today that the European Commission (EC) has granted a marketing authorization for Spinraza for the treatment of spinal muscular atrophy (SMA), making it the first approved treatment in the European Union (EU) for SMA. Spinraza was reviewed under the European Medicines Agency’s (EMA) accelerated assessment program, intended to expedite access to patients with

European Commission Grants Marketing Authorization for Spinraza, Making it First Approved SMA Treatment in the European Union Read More »

Cure SMA Awards $140,000 Grant to Oliver Gruss, PhD, Rheinische Friedrich-Wilhelms-Universitat Bonn and Utz Fischer, PhD, Julius-Maximilians-Universitat Wurzburg, Germany

Leave a Comment / Front Page News, Research /

Cure SMA has awarded a $140,000 research grant to Drs. Oliver Gruss and Utz Fischer at Rheinische Friedrich-Wilhelms-Universitat Bonn and Julius-Maximilians-Universitat Wurzburg in Germany to study “Regulatory cues modulating the activity of SMN in human cells.” This projects aims to understand the details of how SMN protein works in the cell. Drs. Gruss and Fischer

Cure SMA Awards $140,000 Grant to Oliver Gruss, PhD, Rheinische Friedrich-Wilhelms-Universitat Bonn and Utz Fischer, PhD, Julius-Maximilians-Universitat Wurzburg, Germany Read More »

Cytokinetics Receives FDA Orphan Drug Designation for CK-2127107 for SMA

Leave a Comment / Clinical Trials, Front Page News /

Cytokinetics, Inc. recently announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CK-2127107, a next-generation fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Orphan designation is granted to drugs and biologic products that are intended for the safe

Cytokinetics Receives FDA Orphan Drug Designation for CK-2127107 for SMA Read More »

Cure SMA Announces 2017 Family Friendly Poster Session Presenters

Leave a Comment / Conference, Front Page News /

We’ve recently seen significant advances in SMA research come to fruition, and with 17 drug programs in development, including five in clinical trials, we are invested to treating all ages, stages and types of SMA. With such great promise in the research landscape, we know that collaboration between academics, industry, government and families is crucial.

Cure SMA Announces 2017 Family Friendly Poster Session Presenters Read More »

Scroll to Top